|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
1999-7-28
|
|
pubmed:abstractText |
Fas (Apo-1/CD95) is a cell-surface receptor involved in cell death signaling. The key role of the Fas system in negative growth regulation has been studied mostly within the immune system, and somatic mutations of Fas in cancer patients have been described solely in lymphoid-lineage malignancies. We analyzed somatic mutations and loss of heterozygosity of Fas gene in 43 transitional cell carcinomas of urinary bladder. Overall, 12 tumors (28%) were found to have Fas mutations, including 11 missense mutations and 1 frameshift mutation. Ten of the 12 mutations were located in the death domain known to be involved in the transduction of an apoptotic signal, and 8 of these 10 mutations showed an identical G to A transition at bp 993, indicating a potential hotspot in bladder cancers. Three of eight (38%) informative tumors carrying Fas mutations showed LOH at polymorphic sites in the promoter region. This is the first report on the Fas gene mutations in nonlymphoid malignancies, and our data suggest that alterations of the Fas gene might lead to the loss of its apoptotic function and contribute to the pathogenesis of some bladder cancers.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0008-5472
|
|
pubmed:author |
pubmed-author:DoneS SSS,
pubmed-author:JangJ JJJ,
pubmed-author:KimC SCS,
pubmed-author:KimH SHS,
pubmed-author:KimS YSY,
pubmed-author:LeeH KHK,
pubmed-author:LeeJ YJY,
pubmed-author:LeeS HSH,
pubmed-author:MOER ERE,
pubmed-author:OuJ CJC,
pubmed-author:ParkW SWS,
pubmed-author:ShinM SMS,
pubmed-author:YooN JNJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3068-72
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10397246-Amino Acid Substitution,
pubmed-meshheading:10397246-Antigens, CD,
pubmed-meshheading:10397246-Antigens, CD95,
pubmed-meshheading:10397246-Carcinoma, Transitional Cell,
pubmed-meshheading:10397246-DNA Primers,
pubmed-meshheading:10397246-Exons,
pubmed-meshheading:10397246-Fas Ligand Protein,
pubmed-meshheading:10397246-Frameshift Mutation,
pubmed-meshheading:10397246-Humans,
pubmed-meshheading:10397246-Loss of Heterozygosity,
pubmed-meshheading:10397246-Membrane Glycoproteins,
pubmed-meshheading:10397246-Mutation, Missense,
pubmed-meshheading:10397246-Neoplasm Staging,
pubmed-meshheading:10397246-Point Mutation,
pubmed-meshheading:10397246-Polymerase Chain Reaction,
pubmed-meshheading:10397246-Polymorphism, Single-Stranded Conformational,
pubmed-meshheading:10397246-Urinary Bladder Neoplasms
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder.
|
|
pubmed:affiliation |
Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
